Comparative study of the effects of adamantane derivatives on the behavior of CD-1 mice with different phenotype of attention stability
N. A. Sukhorukova, R. M. Salimov, G. I. Kovalev · 2022 · Pharmacokinetics and Pharmacodynamics. 2022;(1):3–8
What does this source report?
Cyclantane, Ladasten and memantine partially restored attention in the low-attention subgroup, but worsened attention in the initially high-attention subgroup by 40–47% relative to controls. Exploratory and locomotor measures did not change in parallel.
- Population and setting
- CD-1 mice separated by baseline attention phenotype; three administrations
- Evidence type
- Animal / experimental
- Preparation
- See the original report; formulation details require verification.
- Source language
- Russian
- Title provenance
- Title as recorded in the linked source or index. A separate original-language title has not been transcribed unless shown above.
What are the limitations?
- Phenotype-dependent mouse behavior is not evidence for human ADHD treatment or general cognitive enhancement.
- Dose, route and repeated-testing effects limit extrapolation; the names Cyclantane and Cyclontane refer here to ADK-638.
Publication counts are not counts of independent trials. Reviews, translations and reports sharing participants may overlap. Findings apply to the studied preparation, population and endpoints.
Document format: Journal article; full-text reproduction
Review depth: Abstract, identity passage and selected methods reviewed
Source access and review scope
Selected source passages checked; complete methods and risk of bias not appraised.
Recorded source-check date: 2026-10-03. This date does not imply a completed systematic review.
Cite and trace this record
Original source: N. A. Sukhorukova, R. M. Salimov, G. I. Kovalev. Comparative study of the effects of adamantane derivatives on the behavior of CD-1 mice with different phenotype of attention stability Pharmacokinetics and Pharmacodynamics. 2022;(1):3–8 2022.
Molekul research summary: https://molekul.io/research/adk-attention-2022. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entryRelated compound profiles
Cyclontane
1-Hydroxy-4-cyclohexylaminoadamantane hydrochloride (ADK-638), an experimental hydroxyadamantane. Individual-compound experiments and the sodium-oxybate formulation are separate evidence.
Bromantane
An adamantane-derived small molecule, also known as Ladasten. The expanded archive connects clinical asthenia studies, operator experiments and preclinical mechanisms, with model-specific limitations and safety findings.